Related Experiment Videos
Glioblastoma multiforme with long term survival
Prabal Deb1, Mehar Chand Sharma, Ashok Kumar Mahapatra
1Department of Pathology, All India Institute of Medical Sciences, New Delhi.
Neurology India
|October 19, 2005
Summary
Glioblastoma multiforme (GBM) with long-term survival (LTS) is rare. Young GBM patients with LTS showed specific histological features and p53 expression, suggesting prognostic value in the absence of definitive markers.
Area of Science:
- Neuro-oncology
- Pathology
- Cancer Research
Background:
- Glioblastoma multiforme (GBM) typically presents a poor prognosis, with a median survival of 10-12 months.
- Long-term survival (LTS) in GBM patients (>= 5 years) is uncommon, and prognostic markers remain elusive.
- Identifying factors associated with favorable outcomes in GBM is crucial for improving patient management.
Purpose of the Study:
- To investigate clinicopathological features and protein expression in GBM patients with LTS.
- To identify potential correlates of favorable prognosis in GBM.
- To evaluate the role of p53, p27, p16, and EGFR in GBM long-term survival.
Main Methods:
- Retrospective analysis of six GBM cases with LTS (5-15 years survival).
- Evaluation of clinicopathological data, including histology and age.
- Immunohistochemical assessment of proliferation index (MIB-1LI), p53, p27, p16, and EGFR protein expression.
Main Results:
- All six LTS GBM patients were young (mean age 27 years).
- Histological variations included conventional GBM, oligodendroglial components, and giant cell GBM.
- Immunohistochemistry revealed a mean MIB-1LI of 12%, p53 positivity in 4/5 cases, and immunonegativity for EGFR and p27 in all cases.
Conclusions:
- In young GBM patients with LTS, histological evaluation for oligodendroglial or giant cell components is important.
- Proliferative index and p53 expression may hold prognostic significance in GBM.
- Further studies are needed to clarify the prognostic role of p16 and p27 in GBM.